BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder

BridgeBio spins gold out of an Alexion castoff, scoring an FDA approval in rare metabolism disorder

Source: 
Endpoints
snippet: 

The FDA approved BridgeBio’s Nulibry (fosdenopterin), once known as ALXN1101, on Friday to treat molybdenum cofactor deficiency type A, an autosomal recessive, inborn error of metabolism caused by mutations in the molybdenum cofactor synthesis 1 gene (MOCS1).